Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 10;9(1):85.
doi: 10.1186/s13045-016-0315-9.

Aberrant splicing and drug resistance in AML

Rosalia de Necochea-Campion  1 , Geoffrey P Shouse  2 , Qi Zhou  1 , Saied Mirshahidi  1 , Chien-Shing Chen  3   4
Affiliations
Review

Aberrant splicing and drug resistance in AML

Rosalia de Necochea-Campion et al. J Hematol Oncol. .

Abstract

The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognized as a prominent component of this disease. This review will focus on how these factors influence drug resistance through altered splicing of tumor suppressor and oncogenes and dysregulation of the apoptotic signaling network. A better understanding of these factors in disease progression is necessary to design appropriate therapeutic strategies recognizing specific alternatively spliced or mutated oncogenic targets.

Keywords: Chemoresistance; Clonal evolution; Mutation; Splice factor; Target.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic diagram of factors influencing aberrant splicing and drug resistance in AML. TF transcription factor, SF splice factor
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ramos NR, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665–695. doi: 10.3390/jcm4040665. - DOI - PMC - PubMed
    1. Dohner H, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474. doi: 10.1182/blood-2009-07-235358. - DOI - PubMed
    1. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924. doi: 10.3324/haematol.2012.066100. - DOI - PMC - PubMed
    1. Eleni LD, Nicholas ZC, Alexandros S. Challenges in treating older patients with acute myeloid leukemia. J Oncol. 2010;2010:943823. doi: 10.1155/2010/943823. - DOI - PMC - PubMed
    1. Hahn CN, et al. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Immunol Rev. 2015;263(1):257–278. doi: 10.1111/imr.12241. - DOI - PubMed

Publication types